TN-CKE-RESTAURANTS
10.5.2021 15:02:12 CEST | Business Wire | Press release
CKE Restaurants Holdings, Inc., the parent company of Carl’s Jr. and Hardee’s , announced the opening of its 1,000th international restaurant in Madrid, Spain, as they continue to bring bold, craveable burgers and flavors to all corners of the globe. The opening marks a key milestone for the brand as it continues to expand its international footprint across Europe, the Americas, Asia, the Middle East, Australia and more.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210510005062/en/
The opening of the new Carl’s Jr. restaurant in Madrid marks the 23rd restaurant in Spain. CKE is continuing to expand across the European market, all the while, delivering new, innovative customer experiences and a menu filled with its impossible-to-ignore flavors.
“The opening of the 1000th international location is a proud moment placing CKE in the top tier of global restaurant chains,” said CEO of CKE Restaurants Ned Lyerly. “Our momentum is building as we have plans to double our international presence in the next five years. We will accelerate growth by focusing on partnerships with exceptional franchise operators who share our vision of offering the most innovative, best tasting food in our industry!”
CKE continues to expand its presence across six continents and has maintained positive same store sales globally for nearly a decade. Earlier this year, the company hit other pivotal international milestones, including opening its 300th restaurant in Mexico; celebrating 40 years of business in the Middle East; expanding across Australia with a flagship restaurant opening in Sydney and later this summer the company will open a restaurant in Charles de Gaulle Airport centered around speed and convenience with a “Grab & Go” station, self-order kiosks and more.
“The 1,000th international restaurant is a major milestone for our company, and we’re thrilled to be able to continue providing guests around the world an iconic taste of California,” said Mike Woida, President of CKE International . “This new Carl’s Jr. location in Spain exemplifies CKE’s commitment to adapt to the consumer landscape and offer new experiences while maintaining craveable flavors.”
With culinary innovation at the forefront, CKE Restaurants will continue to introduce mouth-watering flavors that highlight their brands’ Chargrilled Angus Beef Burgers, crispy Hand-Breaded Chicken Tenders™, their iconic range of products that everyone knows and loves, and additionally CKE will create local adaptations that are region-specific, such as the Morita Burger in Mexico, Poutine in Canada, and more.
Follow Carl’s Jr. and Hardee’s on social media for the latest product news and promotional offers.
Twitter:
@CarlsJr
and @Hardees
Instagram:
@CarlsJr
and @Hardees
Facebook:
www.facebook.com/carlsjr
and www.facebook.com/hardees
About CKE Restaurants Holdings, Inc.
CKE Restaurants Holdings, Inc. (“CKE”), a privately held company based in Franklin, Tennessee, runs and operates Carl’s Jr. and Hardee’s, two beloved regional brands, known for one-of-a-kind premium and innovative menu items such as 100 percent Black Angus Thickburgers®, Made from Scratch™ Biscuits and Hand-Breaded Chicken Tenders™. With both a US and international footprint, Carl’s Jr. Restaurants LLC and Hardee’s Restaurants LLC have over 3,900 franchised or company-operated restaurants in 44 states and 40 foreign countries and U.S. territories. For more information about CKE, please visit www.ckr.com or its brand sites at www.carlsjr.com and www.hardees.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210510005062/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom